(NASDAQ: CDMO) Avid Bioservices's forecast annual revenue growth rate of 21.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.15%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.03%.
Avid Bioservices's revenue in 2023 is $134,183,000.On average, 1 Wall Street analysts forecast CDMO's revenue for 2023 to be $8,723,310,820, with the lowest CDMO revenue forecast at $8,723,310,820, and the highest CDMO revenue forecast at $8,723,310,820. On average, 1 Wall Street analysts forecast CDMO's revenue for 2024 to be $11,838,778,970, with the lowest CDMO revenue forecast at $11,838,778,970, and the highest CDMO revenue forecast at $11,838,778,970.
In 2025, CDMO is forecast to generate $16,200,434,380 in revenue, with the lowest revenue forecast at $16,200,434,380 and the highest revenue forecast at $16,200,434,380.